JP2023530088A5 - - Google Patents

Info

Publication number
JP2023530088A5
JP2023530088A5 JP2022576034A JP2022576034A JP2023530088A5 JP 2023530088 A5 JP2023530088 A5 JP 2023530088A5 JP 2022576034 A JP2022576034 A JP 2022576034A JP 2022576034 A JP2022576034 A JP 2022576034A JP 2023530088 A5 JP2023530088 A5 JP 2023530088A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound according
pharmaceutical composition
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2022576034A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023530088A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/036839 external-priority patent/WO2021252781A1/en
Publication of JP2023530088A publication Critical patent/JP2023530088A/ja
Publication of JP2023530088A5 publication Critical patent/JP2023530088A5/ja
Ceased legal-status Critical Current

Links

JP2022576034A 2020-06-12 2021-06-10 Alk2阻害剤としての活性を有するイミダゾピリダジン化合物 Ceased JP2023530088A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063038410P 2020-06-12 2020-06-12
US63/038,410 2020-06-12
PCT/US2021/036839 WO2021252781A1 (en) 2020-06-12 2021-06-10 Imidazopyridazine compounds with activity as alk2 inhibitors

Publications (2)

Publication Number Publication Date
JP2023530088A JP2023530088A (ja) 2023-07-13
JP2023530088A5 true JP2023530088A5 (https=) 2024-06-17

Family

ID=76971994

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022576034A Ceased JP2023530088A (ja) 2020-06-12 2021-06-10 Alk2阻害剤としての活性を有するイミダゾピリダジン化合物

Country Status (17)

Country Link
US (2) US11840546B2 (https=)
EP (1) EP4165051A1 (https=)
JP (1) JP2023530088A (https=)
KR (1) KR20230025434A (https=)
CN (1) CN115956081A (https=)
AR (1) AR122587A1 (https=)
AU (1) AU2021288107A1 (https=)
BR (1) BR112022025191A2 (https=)
CA (1) CA3184811A1 (https=)
CL (1) CL2022003453A1 (https=)
CO (1) CO2022017969A2 (https=)
EC (1) ECSP22093652A (https=)
IL (1) IL298248A (https=)
MX (1) MX2022015493A (https=)
PE (1) PE20230491A1 (https=)
TW (1) TWI895442B (https=)
WO (1) WO2021252781A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3124088A1 (en) 2018-12-20 2020-06-25 Incyte Corporation Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100786927B1 (ko) 2000-06-28 2007-12-17 스미스클라인비이참피이엘시이 습식 분쇄방법
ATE522249T1 (de) * 2007-07-26 2011-09-15 Novartis Ag Organische verbindungen
AR068877A1 (es) 2007-10-17 2009-12-09 Novartis Ag Derivados heterociclicos de imidazol
CA2806655A1 (en) 2010-07-28 2012-02-02 Bayer Intellectual Property Gmbh Substituted imidazo[1,2-b]pyridazines
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
CA2834901A1 (en) 2011-05-06 2012-11-15 Bayer Intellectual Property Gmbh Substituted imidazopyridines and imidazopyridazines and the use thereof
WO2014160203A2 (en) 2013-03-14 2014-10-02 The Brigham And Women's Hospital, Inc. Bmp inhibitors and methods of use thereof
WO2017070089A1 (en) 2015-10-19 2017-04-27 Incyte Corporation Heterocyclic compounds as immunomodulators
SG10202004618TA (en) 2015-11-19 2020-06-29 Incyte Corp Heterocyclic compounds as immunomodulators
MA44075A (fr) 2015-12-17 2021-05-19 Incyte Corp Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1
AU2016379372A1 (en) 2015-12-22 2018-08-02 Incyte Corporation Heterocyclic compounds as immunomodulators
AR108396A1 (es) 2016-05-06 2018-08-15 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
WO2017205464A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
HUE060256T2 (hu) 2016-06-20 2023-02-28 Incyte Corp Heterociklusos vegyületek mint immunmodulátorok
EP3484866B1 (en) 2016-07-14 2022-09-07 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018044783A1 (en) 2016-08-29 2018-03-08 Incyte Corporation Heterocyclic compounds as immunomodulators
US20190218214A1 (en) 2016-09-14 2019-07-18 Vanderbilt University Inhibition of BMP Signaling Compounds, Compositions and Uses Thereof
MX2019002951A (es) 2016-09-15 2019-09-11 Armstrong World Ind Inc Sistema de techo con movimiento aereo.
LT3558990T (lt) 2016-12-22 2022-12-27 Incyte Corporation Tetrahidroimidazo[4,5-c]piridino dariniai kaip pd-l1 internalizavimo induktoriai
JP7101678B2 (ja) 2016-12-22 2022-07-15 インサイト・コーポレイション 免疫調節剤としての複素環式化合物
ES2874756T3 (es) 2016-12-22 2021-11-05 Incyte Corp Derivados de triazolo[1,5-A]piridina como inmunomoduladores
US20180179202A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018119221A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Pyridine derivatives as immunomodulators
WO2018119263A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds derivatives as pd-l1 internalization inducers
WO2018136634A1 (en) 2017-01-18 2018-07-26 Vanderbilt University Fused heterocyclic compounds as selective bmp inhibitors
WO2018165569A1 (en) 2017-03-10 2018-09-13 Rutgers, The State University Of New Jersey Therapeutic compounds and methods
CA3124088A1 (en) 2018-12-20 2020-06-25 Incyte Corporation Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2

Similar Documents

Publication Publication Date Title
EP2101759B1 (en) Methods of using mek inhibitors
US10227357B2 (en) Compounds and methods for kinase modulation, and indications therefor
TW202327569A (zh) 包含tead抑制劑的藥物組合及其用於癌症治療之用途
JP7182304B2 (ja) インドリノン化合物の使用
RU2472509C2 (ru) Способ лечения артрита
RU2665036C2 (ru) Гетероароматические соединения-модуляторы фосфоинозидит-3-киназы и способы применения
CN109381469A (zh) 喹唑啉衍生物类酪氨酸激酶抑制剂的新用途
JP2009542638A5 (https=)
TW201305170A (zh) 用於治療過度增生病症及與血管生成有關之疾病之胺醇取代之2,3-二氫咪唑并[1,2-c]喹唑啉衍生物
JP2017537948A5 (https=)
RU2016141645A (ru) ИНГИБИТОРЫ TrkA КИНАЗЫ, ОСНОВАННЫЕ НА НИХ КОМПОЗИЦИИ И СПОСОБЫ
JP2017518981A5 (https=)
BR112021006033A2 (pt) Uso de um inibidor de um transportador da família ent no tratamento de câncer e combinação do mesmo com um antagonista do receptor de adenosina
WO2013142427A1 (en) Compounds and methods for kinase modulation, and indications therefor
RU2017121044A (ru) Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы
ES2639402T3 (es) 2,3-dihidroimidazo[1,2-c]quinolinas sustituidas con arilaminoalcohol
EP2726074A1 (en) Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
JP2011525898A5 (https=)
RU2010150786A (ru) Пирролопиридины как ингибиторы киназы
RU2006128426A (ru) Производные тиофенав в качестве ингибиторов снк 1
RU2018134167A (ru) Комбинированная терапия для лечения острого миелоидного лейкоза
JP2005538099A5 (https=)
CN108779073A (zh) 用于治疗癌症的组合物和方法
JP2022521380A5 (https=)
JP2018522861A5 (https=)